Pulmatrix, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.7M
- Price
- $1.55
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.64%
- Volume
- 6.9K
About
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Quick stats
Shares outstanding3.7M
Computed float3.3M
Float / shares89.3%
Cash runway (months)6.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001574235
Websitehttps://www.pulmatrix.com
AI Summary
AI-generated1/8
standardneutralearnings
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Pulmatrix reported a Q2 net loss of $1.0 million with cash and equivalents declining to $2.2 million from $4.1 million at year-end 2025. The company stated that all clinical development remains on hold while it seeks to monetize or out-license its assets.
Management filed a Form S-4 registration statement regarding the proposed merger with Eos SENOLYTIX, which is expected to close in the third quarter of 2026. The company disclosed that its financial statements were prepared on a going concern basis, relying on the successful consummation of this merger.
To support the transaction, Pulmatrix raised $1.0 million in gross proceeds through a private placement of Series B Convertible Preferred Stock. If completed, the merged entity will focus on Eos's pipeline of gerotherapeutic peptides targeting mitochondrial dysfunction.
Red flags
- Going concern assumption relies on consummation of the proposed merger
- All clinical development currently on hold
- Cash balance decreased from $4.1M to $2.2M in six months